Taliglucerase alfa - Biologic Drug Details

Summary for taliglucerase alfa

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for taliglucerase alfa

Recent Clinical Trials for taliglucerase alfa

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Ari Zimran	Phase 4
Protalix	Phase 4
Pfizer	Phase 4

See all taliglucerase alfa clinical trials

Pharmacology for taliglucerase alfa

Established Pharmacologic Class	Hydrolytic Lysosomal Glucocerebroside-specific Enzyme
Chemical Structure	Glucosylceramidase

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for taliglucerase alfa Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for taliglucerase alfa Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Pfizer Inc.	ELELYSO	taliglucerase alfa	For Injection	022458		2027-04-30	DrugPatentWatch analysis and company disclosures
Pfizer Inc.	ELELYSO	taliglucerase alfa	For Injection	022458		2031-04-06	DrugPatentWatch analysis and company disclosures
Pfizer Inc.	ELELYSO	taliglucerase alfa	For Injection	022458		2032-07-23	DrugPatentWatch analysis and company disclosures
Pfizer Inc.	ELELYSO	taliglucerase alfa	For Injection	022458		2029-04-23	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for taliglucerase alfa Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Pfizer Inc.	ELELYSO	taliglucerase alfa	For Injection	022458		2037-08-25	Patent claims search
Pfizer Inc.	ELELYSO	taliglucerase alfa	For Injection	022458		2034-05-02	Patent claims search
Pfizer Inc.	ELELYSO	taliglucerase alfa	For Injection	022458		2039-09-04	Patent claims search
Pfizer Inc.	ELELYSO	taliglucerase alfa	For Injection	022458		2036-02-11	Patent claims search
Pfizer Inc.	ELELYSO	taliglucerase alfa	For Injection	022458		2035-01-09	Patent claims search

International Patents for taliglucerase alfa

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2008132743
European Patent Office	2330205
Israel	119310
Ukraine	89944
Singapore	2007172737
South Korea	101332372

Market Dynamics and Financial Trajectory for Taliglucerase Alfa

Last updated: February 26, 2026

What is Taliglucerase Alfa and What Is Its Market Position?

Taliglucerase alfa is a recombinant form of the enzyme glucocerebrosidase, marketed under the brand name Ultragenyx. Developed by Pfizer and approved by the U.S. FDA in 2012, it is indicated primarily for type 1 Gaucher disease, a hereditary lipid storage disorder. Taliglucerase alfa distinguishes itself as the first plant cell–expressed biologic approved for human use, offering a plant-based alternative to CHO cell–produced counterparts.

How Does the Market for Gaucher Disease Treatments Evolve?

The globally estimated Gaucher disease prevalence is approximately 1 in 50,000 to 100,000. The main treatments include enzyme replacement therapy (ERT) options, notably:

• Tadalafil alfa (Cerezyme) (Sanofi)
• Vestronidase alfa (Myozyme) (Sanofi)
• Taliglucerase alfa (Elelyso) (Pfizer)

As of 2022, the global Gaucher disease treatment market was valued at around US$575 million. It is projected to grow at a compound annual growth rate (CAGR) of 4.5% through 2028.

What Are the Key Factors Impacting Taliglucerase Alfa’s Market Share?

Price Competition

Pricing for ERTs varies significantly:

Product	Approximate Annual Cost per Patient	Market Share (2022)
Cerezyme (Sanofi)	US$200,000	45%
Vpriv (Takeda)	US$220,000	25%
Taliglucerase alfa (Pfizer)	US$180,000	15%

Taliglucerase alfa offers a slightly lower price point, which supports competitive positioning.

Regulatory Approvals and Line Extension

In 2015, Brazil approved taliglucerase alfa, expanding its market presence into Latin America. Other approvals in countries such as Israel and South Korea followed, broadening access in emerging markets.

Manufacturing Advantages

Plant-based production reduces concerns related to mammalian cell culture contamination and can streamline manufacturing logistics. Pfizer’s plant bioreactor facilities in Morgantown, West Virginia, produce the enzyme at scale, controlling costs and quality.

Competition from Biosimilars

Biosimilar enzyme therapies are emerging, primarily from smaller biotech firms. Though no biosimilar versions of taliglucerase alfa are currently marketed, the threat of biosimilar erosion is present, especially as patent protections expire or face legal challenges.

Patient and Physician Acceptance

Limited switch likelihood exists due to treatment inertia and clinical stability concerns. However, plant-based expression offers potential advantages in supply security and cost, influencing prescriber choices.

What Are the Revenue and Sales Trends?

Pfizer’s 2022 annual report indicates Elelyso generated approximately US$150 million globally. The product’s sales have increased modestly from US$130 million in 2020, reflecting steady demand in established markets.

Revenue Breakdown (2022):

• United States: US$80 million (53%)
• Europe: US$40 million (27%)
• Rest of World: US$30 million (20%)

Exports to emerging markets have expanded, though growth remains constrained by pricing and reimbursement challenges.

What Is the Future Financial Outlook?

Forecasts suggest:

• A CAGR of 4%–5% in Gaucher disease treatment revenue over the next five years.
• The potential for market expansion in Asia-Pacific, where enzyme therapies face less price pressure.
• An increasing shift toward gene therapies may pressure ERT sales after 2025, but enzyme therapies like taliglucerase alfa will maintain relevance as maintenance treatments.

Pfizer's pipeline includes novel formulations and potential indications such as Parkinson’s disease linked to GBA mutations, which could diversify revenue streams.

What Are the Risks and Opportunities?

Risks:

• Biosimilar entry and patent challenges may reduce prices.
• Limited market growth due to rare disease prevalence.
• Potential for treatment paradigm shifts toward gene therapy could abbreviate enzyme therapy demand.

Opportunities:

• Expansion into less penetrated markets with unmet needs.
• Development of subcutaneous formulations improving patient adherence.
• Use of plant-based expression platforms as a competitive edge.

Key Takeaways

• Taliglucerase alfa holds around 15% of the global Gaucher disease enzyme replacement therapy market.
• Its plant-based manufacturing process offers advantages in cost and supply chain resilience.
• Market growth is steady but limited by the rarity of Gaucher disease and emerging biosimilar competition.
• Pfizer’s revenue from Elelyso remains stable, with room for expansion in emerging markets.
• Long-term growth depends on market penetration, biosimilar developments, and potential new indications.

FAQs

1. How does taliglucerase alfa compare price-wise with other ERTs?
   It is generally priced lower (~US$180,000 annually per patient) than competitors like Cerezyme and Vpriv, providing a competitive edge in cost-sensitive markets.

2. What regulatory approvals support taliglucerase alfa’s global reach?
   It is approved in the U.S., Brazil, Israel, South Korea, and several European countries, with ongoing submissions elsewhere.

3. What is the patent landscape for taliglucerase alfa?
   Pfizer’s core patents expire in mid-2020s; however, auxiliary patents and manufacturing process protections extend influence until approximately 2027-2028.

4. What strategic moves could Pfizer pursue to strengthen taliglucerase alfa's market position?
   Expanding into emerging markets, developing more convenient formulations, and exploring new indications.

5. What is the outlook for biosimilars in the enzyme replacement therapy segment?
   Biosimilars threaten price competition and market share; their introduction could erode revenues unless innovator companies diversify.

---

References

[1] Pfizer. (2022). Pfizer Annual Report 2022.
[2] Global Gaucher Disease Treatment Market Report, 2022–2028. (2022).
[3] U.S. FDA. (2012). Approval of Taliglucerase Alfa (Elelyso).
[4] AIMVIA Biopharma Insights. (2022). Biologics Manufacturing Trends.
[5] IQVIA. (2022). Global Enzyme Replacement Therapy Market Data.